Printer Friendly

Warfarin can safely prevent stroke in AF patients over 75: prior RCT trials involved younger patients.

VANCOUVER, B.C. -- Thrombo-prophylaxis using warfarin produced a "huge, highly significant, 50% reduction" in death and major disability from stroke in elderly patients with a history of atrial fibrillation, roundly outperforming aspirin prophylaxis in a randomized trial, Dr. Richard Hobbs reported at the annual meeting of the North American Primary Care Research Group.

Feared bleeding complications were no higher than with aspirin therapy in the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) trial, conducted in 262 general practices in England and Wales.

"We think warfarin should be routinely prescribed to any patient presenting with atrial fibrillation, regardless of age," declared Dr. Hobbs, lead investigator for the trial and professor and he ad of primary care and general practice at the University of Birmingham (England) School of Medicine.

The prevalence of atrial fibrillation increases with age, so that 50% of all cases are in patients over 75. It raises the risk of stroke fivefold and accounts for a third of all strokes in the elderly, Dr. Hobbs explained during a paper presentation at the meeting.

However, existing trial data supporting warfarin as a prophylaxis focused heavily on younger patients with atrial fibrillation who are believed to have a very different risk-benefit profile than patients older than 75. Indeed, among the few elderly patients enrolled in large-scale trials, the risk of bleeding events was high enough that the number needed to treat (46) was close to the number needed to harm (55).

"As a consequence of that, many physicians around the world were in equipoise about whether you should treat patients over 75 with warfarin or give them aspirin. Hence, this trial," said Dr. Hobbs.

The BAFTA trial identified more than 58,000 adults over the age of 75 who had been diagnosed with atrial fibrillation or screened for the condition based on an irregular pulse. Of a total of 973 men and women, 488 were randomized to receive warfarin, and 485 were assigned to receive aspirin. They were followed for a mean of 2.7 years.

The trial differed in several ways from original large-scale warfarin/aspirin studies. Patients were a mean age of 81 years, compared with about 60 years.

Reflecting their advanced age, they were also less healthy, with many comorbidities and a relatively high mean CHAD[S.sub.2] score (28% with a score of 3-6 on the stroke risk scale for AF patients of 0-6 points), which reflected an elevated baseline risk of stroke.

Few exclusions prohibited entry into the study "because we wanted it to be relevant to most providers' practices," he said. Patients were not enrolled if they had active peptic ulcer disease, a history of rheumatic heart disease or intracranial hemorrhage, or a major nontraumatic hemorrhage in the past 5 years.

The primary outcome was specified as a fatal or disabling stroke, the latter defined as a stroke resulting in persistent symptoms after 48 hours; intracranial hemorrhage; or significant arterial embolism. Secondary outcomes included major extracranial hemorrhages or major nonstroke vascular events.

Aspirin was given at a dosage of 75 mg/day, and warfarin was prescribed at a target international normalized ratio (INR) of 2.5 within a range of 2-3. Dosages of both drugs were lower than those used in major trials and commonly prescribed by U.S. physicians, said Dr. Hobbs.

The results were clear, he said. "We showed a huge, highly significant, 50% reduction in the primary end point, in terms of death or major disabling stroke."

The patient group receiving warfarin had 1.8 strokes per year, compared with 3.8 per year in the group receiving aspirin. One fatal or disabling stroke per year was prevented for every 50 patients receiving warfarin.

"A very important question is, was that at the expense of bleeding?" he asked. The answer was no, with every major bleeding variable equal between the two groups. A multivariate analysis showed that the results persisted when investigators controlled for age, gender, previous warfarin use, enrollment type (screening or previous atrial fibrillation diagnosis), CHADSe score, and comorbidities. The absolute risk of a major adverse event was 1.9% for patients taking warfarin and 2% for those taking aspirin.

The BAFTA study was funded by the Medical Research Council.

BY BETSY BATES

Los Angeles Bureau
COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Bates, Betsy
Publication:Family Practice News
Date:Nov 15, 2007
Words:708
Previous Article:One in three use inhalers incorrectly.
Next Article:Vitamin E may slow heart disease in select diabetics.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters